Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Rossari Biotech announced Q1 FY27 consolidated revenue of Rs. 697.2 crore, marking a 28% YoY growth, alongside a 4% rise in PAT to Rs. 35.1 crore. The company also established a new greenfield blending facility in Thailand.
Jul 19 2026 16:28:05
Rossari Biotech Ltd - 543213 - Intimation Under Regulation 30 Of SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015
Rossari Biotech's Board of Directors met on July 18, 2026, approving the unaudited financial results for Q1 FY27. Other key approvals included granting 4,000 employee stock options and transferring shareholding of an overseas subsidiary for internal group restructuring.
Jul 18 2026 17:02:06
Rossari Biotech Ltd - 543213 - Intimation Of Grant Of Options Under Rossari Employee Stock Option Plan- 2019
Rossari Biotech's Board approved the transfer of 100% shareholding of Rossari International Limited Company (RILC) to Rossari (Singapore) Pte. Ltd. for Rs. 24 crore. This internal group restructuring aims to consolidate overseas subsidiaries under a single holding platform, with no expected material impact on consolidated financials.
Jul 18 2026 16:56:24
Rossari Biotech Ltd - 543213 - Board Meeting Outcome for Outcome Of Board Meeting Held On July 18, 2026.
Rossari Biotech's Board approved Q1 FY27 financial results. Consolidated revenue increased 28.2% YoY to ₹697.20 cr, and net profit rose 4.5% YoY to ₹35.10 cr. Standalone figures also saw significant growth.
Jul 18 2026 16:32:49
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Rossari Biotech announced an earnings conference call for investors and analysts on July 20, 2026, at 5:00 PM IST. The call will discuss Q1 FY27 financial results, which are expected to be declared on July 18, 2026.
Jul 14 2026 20:38:41
Rossari Biotech Ltd - 543213 - Board Meeting Intimation for Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended June 30, 2026
Rossari Biotech's Board of Directors will hold a meeting on July 18, 2026, to consider and approve the financial results for the quarter ended June 30, 2026. This is a routine update for the upcoming quarterly earnings announcement.
Jul 10 2026 22:42:22
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Rossari Biotech's Board has recommended a final dividend of Re. 0.50 per equity share (25% of face value) for the financial year ended March 31, 2026. This dividend is subject to approval at the upcoming AGM, with July 10, 2026, fixed as the record date for eligibility.
Jun 28 2026 12:25:25
Rossari Biotech Ltd - 543213 - Business Responsibility and Sustainability Reporting (BRSR)
Rossari Biotech's Business Responsibility and Sustainability Report for FY2025-26 indicates notable progress in ESG metrics. The company achieved improvements in energy and water intensity, reduced Scope 1 GHG emissions by 37.25%, and significantly increased waste recycling.
Jun 27 2026 01:00:30
Rossari Biotech Ltd - 543213 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Rossari Biotech's subsidiary, Unistar Thai Co. Limited, has established a new blending facility in Thailand. This facility, with an installed capacity of 5000 MTPA, is strategically positioned to serve the growing Southeast Asian market.
Jun 26 2026 17:48:32
Read More